What's Hot

View all perspectives
      Ab2674 #ACR24
      ➡️Most pts starting 1st-line TNFi, who didn't achieve treatment response at 3M, also didn't achieve re

      Mrinalini Dey DrMiniDey

      1 month ago
      Ab2674 #ACR24 ➡️Most pts starting 1st-line TNFi, who didn't achieve treatment response at 3M, also didn't achieve response from months 3-12 ➡️1/4 pts achieving LDA/remission at 3M were no longer in LDA/remission at 12M @RheumNow https://t.co/pFOo86tJTx
      Data from the RISE registry show that 9.3% of SLE pts had thrombocytopenia and a smaller percentage with mod-severe TP (

      sheila RHEUMarampa

      1 month ago
      Data from the RISE registry show that 9.3% of SLE pts had thrombocytopenia and a smaller percentage with mod-severe TP (2.7%). Severe TP was much rare. Large data, but well represented grp? @RheumNow #ACR24 abs2680 https://t.co/Y1Lo9lJGtO
      An early favorable response to TNFi initiation indicates better long-term success in RA. Assess early and adjust treatme

      Jiha Lee JihaRheum

      1 month ago
      An early favorable response to TNFi initiation indicates better long-term success in RA. Assess early and adjust treatment accordingly. #ACR24 @RheumNow ABST#2674 https://t.co/YTThYiiLpZ
      #ACR24 BEST Abstracts from Day 1

      The RheumNow faculty have parked at the plenaries, trafficked the posters and have bee

      Dr. John Cush RheumNow

      1 month ago
      #ACR24 BEST Abstracts from Day 1 The RheumNow faculty have parked at the plenaries, trafficked the posters and have been finding the best the meeting offers on the first day. https://t.co/FHu616Jpyq https://t.co/oKuRcGRRAZ
      Would you trust #AI to carry out & read your #USS?

      2 systems, ARTHUR & DIANA, were comparable to that of a rheu

      Mrinalini Dey DrMiniDey

      1 month ago
      Would you trust #AI to carry out & read your #USS? 2 systems, ARTHUR & DIANA, were comparable to that of a rheumatologist specialising in MSK US at joint & patient levels Might this be the future of assessment in rheumatology care? AbL20 #ACR24 @RheumNow https://t.co/XtnlYafzp4
      Nailfold video capillaroscopy (NVC) allows the definite distinction between primary and secondary #Raynaud's phenomenon

      sheila RHEUMarampa

      1 month ago
      Nailfold video capillaroscopy (NVC) allows the definite distinction between primary and secondary #Raynaud's phenomenon and can identify early changes such as few giant capillaries &/or microhemorrages promoting early diagnosis @RheumNow #ACR24 @rheumarhyme https://t.co/Yl37w6BEZR
      Another + #SLE #RCT - large N

      #Dapirolizumab = Peg CD40L + SoC
      Vs
      #Placebo + SoC

      Rapid improvemt
      steroid sparing

      S

      Janet Pope Janetbirdope

      1 month ago
      Another + #SLE #RCT - large N #Dapirolizumab = Peg CD40L + SoC Vs #Placebo + SoC Rapid improvemt steroid sparing So what to use in Pts if +Ph3 👇 TYK2 Deucravacitinib JAKi Upadacitinib Dapirolizumab CAR 🚗 Rx Anifrolimumab Benlysta ETC! #ACRBest L16 @RheumNow #ACR24 https://t.co/wTFucF7BYO
      Late breaking abstract L17
      CAR-NK Therapy for Refractory SLE.
      In a trial of 20 severe SLE patients:
      - 75% achieved LLDAS

      Antoni Chan MD (Prof) synovialjoints

      1 month ago
      Late breaking abstract L17 CAR-NK Therapy for Refractory SLE. In a trial of 20 severe SLE patients: - 75% achieved LLDAS, 50% achieved DORIS remission at 6 months - B cell reconstitution: 2–3 months post-treatment - Safety: 2 mild cytokine release syndrome with fever; no severe… https://t.co/MS8cutm48o
      The combe-like pattern is observed in pts with APS and also in overlap syndrome
      - presence of parallel microthrombi (ora

      sheila RHEUMarampa

      1 month ago
      The combe-like pattern is observed in pts with APS and also in overlap syndrome - presence of parallel microthrombi (orange arrow) arranged perpendicularly, hence combe-like @RheumNow #ACR24 @rheumarhyme https://t.co/IjX7ld9lxW
      The #scleroderma-like pattern on NVC is observed in pts with #dermatomyositis and MCTD
      It consists of a combination of g

      sheila RHEUMarampa

      1 month ago
      The #scleroderma-like pattern on NVC is observed in pts with #dermatomyositis and MCTD It consists of a combination of giant capillaries, some microhemorrhages, severe capillary loss and angiogenesis @RheumNow #ACR24 @rheumarhyme https://t.co/WO9BOYn4ir
      In Vivo CAR T Cell Therapy.
      A single intralymphatic injection of VivoVec™ particles:
      - Generates functional CAR T cell

      Antoni Chan MD (Prof) synovialjoints

      1 month ago
      In Vivo CAR T Cell Therapy. A single intralymphatic injection of VivoVec™ particles: - Generates functional CAR T cells in vivo - Achieves complete B cell depletion in NHPs without lymphodepletion - Demonstrates potential for an off-the-shelf solution for autoimmune disease… https://t.co/5DTzRvZjbY https://t.co/DvTOqnhn1V
      Are weight loss drugs in #high #BMI
      In
      #Rheumatoid #arthritis

      A #DMARD?

      Yr in preview #ACR24 @RheumNow @ACRheum http

      Janet Pope Janetbirdope

      1 month ago
      Are weight loss drugs in #high #BMI In #Rheumatoid #arthritis A #DMARD? Yr in preview #ACR24 @RheumNow @ACRheum https://t.co/Hd1y0fFYxY
      Wt ⬇️ = Better #PROs in

      👇autoimmune #rheumatic #diseases if > 5% wt loss.

      #ACR24 ⁦@ACRheum⁩ ⁦@RheumN

      Janet Pope Janetbirdope

      1 month ago
      Wt ⬇️ = Better #PROs in 👇autoimmune #rheumatic #diseases if > 5% wt loss. #ACR24 ⁦@ACRheum⁩ ⁦@RheumNow⁩ Didn’t work for non overwt Ex Normal BMI and T2DM 🤷 https://t.co/81OuTfZ0Nx
      🚨 New SLE treatment update! 🚨 Dapirolizumab pegol (DZP), novel CD40L inhibitor, for moderate-to-severe lupus. Phas

      Bella Mehta bella_mehta

      1 month ago
      🚨 New SLE treatment update! 🚨 Dapirolizumab pegol (DZP), novel CD40L inhibitor, for moderate-to-severe lupus. Phase 3 trial, DZP reduced disease activity, helped taper steroids, and achieved a higher BICLA Safe and generally well tolerated! #ACR24 #L16 @rheumnow https://t.co/lFrKjz4CZ1
      In this study by Dr CArriens et al, there was no difference between the vaccine response to Influenza by either HAI or A

      sheila RHEUMarampa

      1 month ago
      In this study by Dr CArriens et al, there was no difference between the vaccine response to Influenza by either HAI or Ab levels in Anifrolumab-treated pts. AEs - mild, moderate No serious aEs 💉#vaccinate your pts on anifrolumab with influenza @RheumNow #ACR24 abs2424 https://t.co/XPwlzUS02i

      Podcasts

      • Bah Humbug Vitamin D (12.20.2024)
      • 54K Peptic Ulcers Annually (12.13.2024)
      • Don’t Buy Guitars (12.6.2024)

      Catch up on Conference Podcasts

      Key Conference Topics

      Additional Topics

      Filter by Type

      Featured Video

      Do you get our email newsletter?

      Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

      Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

      Copyright 2024 All Rights Reserved.

      ×